🚀 VC round data is live in beta, check it out!
Enliven Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Enliven Therapeutics and similar public comparables like Faes Farma, Vericel, Relay Therapeutics, Galecto and more.
Enliven Therapeutics Overview
About Enliven Therapeutics
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Founded
2019
HQ
Employees
62
Website
Sectors
Financials (LTM)
EV
$1B
Enliven Therapeutics Financials
Enliven Therapeutics reported last 12-month revenue of — and negative EBITDA of ($125M).
In the same LTM period, Enliven Therapeutics generated ($125M) in EBITDA losses and had net loss of ($110M).
Revenue (LTM)
Enliven Therapeutics P&L
In the most recent fiscal year, Enliven Therapeutics reported revenue of — and EBITDA of ($119M).
Enliven Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($125M) | XXX | ($119M) | XXX | XXX | XXX |
| Net Profit | ($110M) | XXX | ($104M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Enliven Therapeutics Stock Performance
Enliven Therapeutics has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Enliven Therapeutics' stock price is $29.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $-1.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEnliven Therapeutics Valuation Multiples
Enliven Therapeutics trades at (10.3x) EV/EBITDA.
EV / Revenue (LTM)
Enliven Therapeutics Financial Valuation Multiples
As of March 21, 2026, Enliven Therapeutics has market cap of $2B and EV of $1B.
Equity research analysts estimate Enliven Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Enliven Therapeutics has a P/E ratio of (16.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/EBITDA | (10.3x) | XXX | (10.8x) | XXX | XXX | XXX |
| EV/EBIT | (10.2x) | XXX | (10.7x) | XXX | XXX | XXX |
| P/E | (16.1x) | XXX | (17.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (18.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Enliven Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Enliven Therapeutics Margins & Growth Rates
Enliven Therapeutics' revenue in the last fiscal year grew by —.
Enliven Therapeutics' revenue per employee in the last FY averaged $0.0M.
Enliven Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 24% | XXX | 20% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Enliven Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Faes Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Vericel | XXX | XXX | XXX | XXX | XXX | XXX |
| Relay Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Galecto | XXX | XXX | XXX | XXX | XXX | XXX |
| Intellia Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Enliven Therapeutics M&A Activity
Enliven Therapeutics acquired XXX companies to date.
Last acquisition by Enliven Therapeutics was on XXXXXXXX, XXXXX. Enliven Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Enliven Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEnliven Therapeutics Investment Activity
Enliven Therapeutics invested in XXX companies to date.
Enliven Therapeutics made its latest investment on XXXXXXXX, XXXXX. Enliven Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Enliven Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Enliven Therapeutics
| When was Enliven Therapeutics founded? | Enliven Therapeutics was founded in 2019. |
| Where is Enliven Therapeutics headquartered? | Enliven Therapeutics is headquartered in United States. |
| How many employees does Enliven Therapeutics have? | As of today, Enliven Therapeutics has over 62 employees. |
| Who is the CEO of Enliven Therapeutics? | Enliven Therapeutics' CEO is Richard A. Fair. |
| Is Enliven Therapeutics publicly listed? | Yes, Enliven Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Enliven Therapeutics? | Enliven Therapeutics trades under ELVN ticker. |
| When did Enliven Therapeutics go public? | Enliven Therapeutics went public in 2023. |
| Who are competitors of Enliven Therapeutics? | Enliven Therapeutics main competitors are Faes Farma, Vericel, Relay Therapeutics, Galecto. |
| What is the current market cap of Enliven Therapeutics? | Enliven Therapeutics' current market cap is $2B. |
| Is Enliven Therapeutics profitable? | No, Enliven Therapeutics is not profitable. |
| What is the current EBITDA of Enliven Therapeutics? | Enliven Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Enliven Therapeutics? | Current EBITDA multiple of Enliven Therapeutics is (10.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.